CO4940452A1 - Modificacion a cristal de una sustancia activa de medicamen- to - Google Patents

Modificacion a cristal de una sustancia activa de medicamen- to

Info

Publication number
CO4940452A1
CO4940452A1 CO98032879A CO98032879A CO4940452A1 CO 4940452 A1 CO4940452 A1 CO 4940452A1 CO 98032879 A CO98032879 A CO 98032879A CO 98032879 A CO98032879 A CO 98032879A CO 4940452 A1 CO4940452 A1 CO 4940452A1
Authority
CO
Colombia
Prior art keywords
crystal modification
medicinal substance
active medicinal
modification
difluorbenzyl
Prior art date
Application number
CO98032879A
Other languages
English (en)
Inventor
Robert Portmann
Christoph Hofmeier Urs
Andreas Burkhard
Walter Scherrer
Martin Szelagiewcz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4940452A1 publication Critical patent/CO4940452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a la nueva modificación A, o bien, A´del compuesto 1-(2,6-difluorbencil)-1H-1,2,3- triazol-4-carboxamida de la fórmula y un preparado farmacéutico que contiene la modificación A, o bien, A´ del compuesto 1-(2,6-difluorbencil)-1H-1,2,3-triazol-4-carboxamida y auxiliares y aditivos farmacéuticamente empleables.
CO98032879A 1997-06-10 1998-06-09 Modificacion a cristal de una sustancia activa de medicamen- to CO4940452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10

Publications (1)

Publication Number Publication Date
CO4940452A1 true CO4940452A1 (es) 2000-07-24

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
CO98032879A CO4940452A1 (es) 1997-06-10 1998-06-09 Modificacion a cristal de una sustancia activa de medicamen- to
CO98032885A CO4940448A1 (es) 1997-06-10 1998-06-09 Modificacion a cristal de una sustancia de medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO98032885A CO4940448A1 (es) 1997-06-10 1998-06-09 Modificacion a cristal de una sustancia de medicamento

Country Status (37)

Country Link
US (6) US6740669B1 (es)
EP (2) EP0994864B1 (es)
JP (2) JP3672574B2 (es)
KR (2) KR100425656B1 (es)
CN (3) CN1159300C (es)
AR (4) AR012946A1 (es)
AT (2) ATE237599T1 (es)
AU (2) AU725517B2 (es)
BR (2) BR9804947A (es)
CA (3) CA2614926C (es)
CO (2) CO4940452A1 (es)
CY (1) CY2007014I1 (es)
CZ (2) CZ292260B6 (es)
DE (3) DE122007000051I2 (es)
DK (2) DK0994864T3 (es)
ES (2) ES2192779T3 (es)
FR (1) FR07C0037I2 (es)
HK (3) HK1028242A1 (es)
HU (2) HU226107B1 (es)
ID (2) ID27660A (es)
IL (2) IL125733A (es)
LU (1) LU91345I2 (es)
MY (2) MY120156A (es)
NL (1) NL300284I2 (es)
NO (2) NO329314B1 (es)
NZ (2) NZ331371A (es)
PE (2) PE79799A1 (es)
PL (2) PL191943B1 (es)
PT (1) PT994864E (es)
RU (2) RU2198167C2 (es)
SI (2) SI0994864T1 (es)
SK (2) SK283685B6 (es)
TR (2) TR199801631T1 (es)
TW (2) TW403740B (es)
UY (1) UY25844A1 (es)
WO (2) WO1998056773A1 (es)
ZA (2) ZA984967B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE60319980T2 (de) * 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
AU2009305255B2 (en) 2008-10-13 2014-02-06 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
WO2011028288A1 (en) * 2009-09-04 2011-03-10 Tactical Therapeutics, Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
JP2013525413A (ja) * 2010-04-30 2013-06-20 ラボラトリオス レスヴィ，エス．エル． ルフィナマイド中間体の改良された製造方法
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (fi) * 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
WO1991001724A1 (en) 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DE69132340T2 (de) 1990-11-06 2001-02-08 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
WO1996026197A1 (en) 1995-02-22 1996-08-29 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
JP3537147B2 (ja) * 1996-07-11 2004-06-14 ノバルティス アクチエンゲゼルシャフト １―置換４―シアノ―１，２，３―トリアゾールの製造法
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
PE79799A1 (es) 1999-09-03
CN1159300C (zh) 2004-07-28
SI0994863T1 (en) 2003-08-31
PE80999A1 (es) 1999-09-06
ES2197485T3 (es) 2004-01-01
HUP0002113A2 (hu) 2001-02-28
AU725528B2 (en) 2000-10-12
AR012945A1 (es) 2000-11-22
KR19990087835A (ko) 1999-12-27
RU2194041C2 (ru) 2002-12-10
HU226107B1 (en) 2008-04-28
AU8437298A (en) 1998-12-30
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
TW403740B (en) 2000-09-01
NZ331370A (en) 2000-08-25
AR061004A2 (es) 2008-07-30
EP0994863A1 (en) 2000-04-26
NO983666L (no) 1998-12-17
TW526195B (en) 2003-04-01
WO1998056772A1 (en) 1998-12-17
ATE232852T1 (de) 2003-03-15
HUP0002113A3 (en) 2002-09-30
ZA984967B (en) 1999-01-11
CN1572789A (zh) 2005-02-02
HU225153B1 (en) 2006-07-28
CZ253498A3 (cs) 1999-04-14
ATE237599T1 (de) 2003-05-15
CA2614926A1 (en) 1998-12-17
HK1028031A1 (en) 2001-02-02
US7750028B2 (en) 2010-07-06
ID21014A (id) 1999-04-08
HK1028241A1 (en) 2001-02-09
PL192114B1 (pl) 2006-08-31
KR100425656B1 (ko) 2004-05-17
MY125854A (en) 2006-08-30
CY2007014I2 (el) 2009-11-04
BR9804947A (pt) 1999-08-24
AR061005A2 (es) 2008-07-30
IL125733A (en) 2002-12-01
TR199801630T1 (xx) 1999-06-21
EP0994863B1 (en) 2003-02-19
PL330764A1 (en) 1999-05-24
PT994864E (pt) 2003-07-31
US20010037029A1 (en) 2001-11-01
DE122007000051I1 (de) 2007-11-08
MY120156A (en) 2005-09-30
FR07C0037I1 (es) 2007-08-17
ID27660A (id) 2001-04-19
CN1217716A (zh) 1999-05-26
DK0994864T3 (da) 2003-07-21
IL125732A (en) 2002-12-01
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
KR100409168B1 (ko) 2004-01-31
CZ292481B6 (cs) 2003-09-17
US6455556B2 (en) 2002-09-24
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
TR199801631T1 (xx) 1999-06-21
PL330798A1 (en) 1999-06-07
US20060116520A1 (en) 2006-06-01
SI0994864T1 (en) 2003-10-31
US8076362B2 (en) 2011-12-13
KR19990087836A (ko) 1999-12-27
NO329315B1 (no) 2010-09-27
NZ331371A (en) 2000-08-25
SK283685B6 (sk) 2003-12-02
CA2256015C (en) 2008-06-03
SK109398A3 (en) 1998-12-02
SK109498A3 (en) 1998-12-02
DE69811500T2 (de) 2004-04-01
CA2256013A1 (en) 1998-12-17
UY25844A1 (es) 2001-08-27
CA2614926C (en) 2010-02-09
JP2000516259A (ja) 2000-12-05
CO4940448A1 (es) 2000-07-24
JP2000516258A (ja) 2000-12-05
JP3672574B2 (ja) 2005-07-20
AU725517B2 (en) 2000-10-12
CA2256015A1 (en) 1998-12-17
HK1028242A1 (en) 2001-02-09
US20100310655A1 (en) 2010-12-09
EP0994864B1 (en) 2003-04-16
HUP0000798A2 (hu) 2000-10-30
US20030125568A1 (en) 2003-07-03
US20040167186A1 (en) 2004-08-26
NO983666D0 (no) 1998-08-11
PL191943B1 (pl) 2006-07-31
IL125732A0 (en) 1999-04-11
DE69813560T2 (de) 2004-02-05
CN1132820C (zh) 2003-12-31
DE69813560D1 (de) 2003-05-22
ES2192779T3 (es) 2003-10-16
NL300284I2 (nl) 2007-11-01
CZ253398A3 (cs) 1999-04-14
CZ292260B6 (cs) 2003-08-13
NO329314B1 (no) 2010-09-27
NO983667L (no) 1998-12-17
HUP0000798A3 (en) 2000-10-30
JP3672575B2 (ja) 2005-07-20
BR9804946A (pt) 1999-08-24
ZA984966B (en) 1999-01-11
LU91345I2 (fr) 2007-09-04
EP0994864A1 (en) 2000-04-26
IL125733A0 (en) 1999-04-11
RU2198167C2 (ru) 2003-02-10
CA2256013C (en) 2007-10-16
AR012946A1 (es) 2000-11-22
CN1259127A (zh) 2000-07-05
FR07C0037I2 (es) 2008-05-16
DE69811500D1 (de) 2003-03-27
CN1298708C (zh) 2007-02-07
DE122007000051I2 (de) 2009-02-19
US6740669B1 (en) 2004-05-25
DK0994863T3 (da) 2003-05-26
LU91345I9 (es) 2018-12-31

Similar Documents

Publication Publication Date Title
SE8804629D0 (sv) New therapeutically active compounds
SE9504661D0 (sv) New compounds
ES2145913T3 (es) Inhibidores de metaloproteasas.
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
EA200200571A1 (ru) Новая композиция и ее применение
DK581889A (da) Antiatherosclerotiske diarylforbindelser
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
ATE360428T1 (de) Analgetisches arzneimittel
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
SE9504662D0 (sv) New compounds
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
SE9504267D0 (sv) New therapeutic use
NO950177L (no) Farmakologisk aktive erivater
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
NO170151C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-(1-aryl-2-hydroksyetyl)-imidazoler og salter derav
ECSP982521A (es) Modificacion a cristal de una sustancia activa de medicamento (i)
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
ECSP982522A (es) Modificacion a cristal de una sustancia activa de medicamento (ii)
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.